Allogene Therapeutics is a clinical-stage biotechnology company, focusing on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.

Developing off-the-shelf CAR T cell therapy candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients. These off-the-shelf CAR T therapies, enhanced by gene editing, could be the next most important breakthrough in the field.

Allogene is on a mission to create and lead the next revolution in cancer treatment by delivering to patients the first AlloCAR T™ therapies for blood cancers and solid tumors.